Opinion

Video

Assessing Risk in NMIBC: A Foundation for Therapy

Panelists discuss how precise risk stratification in non–muscle-invasive bladder cancer enables physicians to tailor treatment and surveillance strategies based on individual patient risk profiles.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Physician Summary:

      Effective management of non–muscle-invasive bladder cancer (NMIBC) hinges on precise risk stratification. Accurate assessment of patient risk is foundational, guiding the choice of treatment intensity, surveillance frequency, and decisions around intravesical therapy. Physicians are encouraged to incorporate key clinical and pathological factors—such as tumor grade, stage, size, multiplicity, recurrence rate, and presence of carcinoma in situ—into a structured risk model. This tailored approach ensures optimized patient outcomes by aligning treatment strategies with the individual’s recurrence and progression risk.

      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.